Jun Bei Liu, lead portfolio manager with Tribeca Investment Partners, talks to Livewire Markets about CSL’s strong result.
CSL has delivered a solid FY19 result with a constant currency net profit after tax of $2,015m, up 11% vs the previous corresponding period.
The strong result was underpinned by the group’s core immune globulin franchise with sales up 16% supported by both strong volumes (reflecting market share gains) and higher prices. The lift in average prices reflected higher European prices and a positive mix benefit as higher priced subcutaneous IG products grew more rapidly.
To read the full article, click here.
The views expressed are her own and do not consider the circumstances of any investor.
